November 4, 2021
Life Sciences
  • U.K. regulators authorized Merck & Co.’s COVID-19 antiviral pill molnupiravir, making it first in the world to clear the treatment. The FDA is still reviewing the drug, though the federal government made an advance purchase of 1.7 million courses of the treatment for roughly $1.2 billion. The treatment slashed hospitalizations among high-risk patients in a clinical trial. (Articles here, here, here, here, here, and here)